Valerio Therapeutics (FR:ALVIO)
:ALVIO
Top Page
Valerio Therapeutics
(ALVIO)
Select Model
Select Model
Rating:47Neutral
Price Target:
€0.16
▲(158.33% Upside)
Action:ReiteratedDate:12/31/25
The score is held down primarily by weak financial performance (declining revenue, ongoing losses, negative equity, and negative cash flows). Technicals provide some support as the price is trading above key moving averages with a neutral-to-mildly positive RSI, but valuation remains unattractive/unclear due to negative earnings and no dividend yield.
Positive Factors
Gross Profit Margin
A strong gross profit margin indicates efficient production and pricing strategies, providing a buffer against operational challenges and potential cost increases.
Negative Factors
Declining Revenue
A declining revenue trend can hinder the company's ability to invest in R&D and other growth initiatives, potentially impacting long-term competitiveness and market position.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross Profit Margin
A strong gross profit margin indicates efficient production and pricing strategies, providing a buffer against operational challenges and potential cost increases.
Read all positive factors
Valerio Therapeutics (ALVIO) vs. iShares MSCI France ETF (EWQ)
Market Cap
€64.82M
Dividend YieldN/A
Average Volume (3M)1.36M
Price to Earnings (P/E)―
Beta (1Y)-0.92
Revenue Growth-3.12%
EPS Growth30.49%
CountryFR
Employees38
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding499,448,300
10 Day Avg. Volume527,429
30 Day Avg. Volume1,357,798
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-1.29
Price to Sales (P/S)6.44
P/FCF Ratio-0.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Valerio Therapeutics Business Overview & Revenue Model
Company Description
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develo...
How the Company Makes Money
Valerio Therapeutics generates revenue primarily through the commercialization of its pharmaceutical products, including sales from approved therapies and potential royalties from licensed drugs. Additionally, the company may pursue partnerships a...
Valerio Therapeutics Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
20
Very Negative
Cash Flow
30
Negative
| Breakdown | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.79M | 1.80M | 1.44M | 4.06M | 1.78M |
| Gross Profit | 1.28M | 1.27M | 929.00K | 3.69M | 1.43M |
| EBITDA | -12.06M | -18.44M | -17.04M | -5.86M | 2.33M |
| Net Income | -23.93M | -20.34M | -19.56M | -5.94M | 1.09M |
Balance Sheet | |||||
| Total Assets | 17.93M | 35.27M | 43.09M | 53.06M | 46.51M |
| Cash, Cash Equivalents and Short-Term Investments | 1.18M | 6.82M | 14.59M | 17.89M | 14.52M |
| Total Debt | 13.44M | 9.00M | 10.09M | 9.94M | 6.26M |
| Total Liabilities | 26.19M | 20.47M | 20.82M | 20.12M | 17.47M |
| Stockholders Equity | -8.93M | 14.80M | 22.27M | 32.94M | 29.04M |
Cash Flow | |||||
| Free Cash Flow | -12.78M | -18.78M | -9.93M | -8.71M | -4.80M |
| Operating Cash Flow | -12.46M | -18.60M | -9.44M | -8.57M | -4.68M |
| Investing Cash Flow | -1.39M | -177.00K | -409.00K | -66.00K | 6.01M |
| Financing Cash Flow | 4.21M | 10.76M | 6.46M | 11.98M | 7.48M |
Valerio Therapeutics Technical Analysis
Positive
0.06
Price Trends
0.14
Negative
0.14
Negative
0.11
Positive
Market Momentum
>-0.01
Negative
55.48
Neutral
88.41
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVIO, the sentiment is Positive. The current price of 0.06 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.14, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.48 is Neutral, neither overbought nor oversold. The STOCH value of 88.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALVIO.
Valerio Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €217.09M | -2.10 | -634.16% | ― | 111.76% | -22.45% | |
49 Neutral | €69.94M | -1.87 | -52.76% | ― | -96.92% | -175.84% | |
47 Neutral | €64.82M | -12.25 | 146.07% | ― | -3.12% | 30.49% | |
45 Neutral | €20.60M | -1.29 | 51.23% | ― | -92.35% | 63.25% | |
44 Neutral | €109.00M | -1.31 | -658.91% | ― | -75.86% | -30.54% | |
44 Neutral | €230.57M | -7.03 | -30.75% | ― | 150.80% | 67.81% |
* Healthcare Sector Average
FR:ALVIO
Valerio Therapeutics
0.13
0.07
113.11%
FR:IPH
Innate Pharma SA
1.16
-0.54
-31.81%
FR:TNG
Transgene
0.78
0.15
23.50%
FR:OSE
OSE Immunotherapeutics SA
3.12
-2.31
-42.58%
FR:SIGHT
GenSight Biologics SA
0.09
-0.15
-63.83%
FR:ALCLS
Cellectis SA
3.19
1.89
144.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.